Lantern Pharma and Oregon Therapeutics Join Forces to Optimize XCE853 for Drug-Resistant Cancer

Lantern Pharma Inc. and Oregon Therapeutics have recently announced a strategic collaboration aimed at optimizing the development of XCE853, a promising first-in-class protein disulfide isomerase (PDI) inhibitor, across a spectrum of cancer indications. This collaboration is significant not only for its potential to advance cancer therapeutics but also for its integration of cutting-edge artificial intelligence (AI) technology into the drug development process.

At the heart of this collaboration lies Lantern Pharma's proprietary RADR® AI platform, which is designed to harness the power of AI in uncovering biomarkers and efficacy-associated signatures of XCE853 across various solid tumors. By leveraging RADR®'s capabilities, the partners seek to gain deeper insights into the mechanisms of action of XCE853 and its potential efficacy in different cancer types.